Assertio Therapeutics Inc. (ASRT)
Symbol Info
Listed Symbol ASRT
Name Assertio Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $311,770,000
Latest Fiscal EPS $0.44
Price Info
21 Day Moving Average $1.3919
21 Day EMA $1.508930
50 Day Moving Average $2.1948
50 Day EMA $2.037870
200 Day EMA $3.572700
200 Day Moving Average 3.645250
52 Week High $6.24
52 Week Low $1.23
52 Week Change $-76.460495
Alpha -0.035221
Beta 1.8984
Standard Deviation 0.185362
R2 0.124641
Periods 60
Share Information
10 Day Average Volume 1,336,300
20 Day Average Volume 1,463,710
30 Day Average Volume 1,925,775
50 Day Average Volume 1,381,343
Outstanding Shares 80,626,248
Float Shares 77,462,664
Percent Float 96.08%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 332
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 7,204,791
Institute Holdings Percent -
Institute Sold Previous 3 Months 5,660,135
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 3,163,584
Price Change
7 Day Price Change $-0.02
7 Day Percent Change -1.44%
21 Day Price Change $-0.02
21 Day Percent Change -1.44%
30 Day Price Change $-0.25
30 Day Percent Change -15.43%
Month To Date Price Change $-0.07
Month To Date Percent -4.86%
90 Day Price Change $-1.63
90 Day Percent Change -54.33%
Quarter To Date $-2.08
Quarter To Date Percent -60.29%
180 Day Price Change $-2.66
180 Day Percent Change -66.01%
200 Day Price Change $-2.95
200 Day Percent Change -68.29%
Year To Date $-2.24
Year To Date Percent -62.05%
Profile
Description Assertio Therapeutics Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid filled capsules for relief of mild to moderate pain.
Details
Issue Type CS
Market Cap $110,457,960
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 80,626,248
CEO Arthur J. Higgins
Employees 116
Last Audit UQ
Classification
CIK 0001005201
Industry Drug Manufacturers
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 100 South Saunders Road
Suite 300
Lake Forest, IL 60045
Website https://www.assertiotx.com
Facisimile +1 510 744-8001
Telephone +1 224 419-7106
Email investors@assertiotx.com
Key Ratios
Profitability
EBIT Margin 27.30
EBITDA Margin 71.6
Pre-Tax Profit Margin -2.1
Profit Margin Cont -1.73
Gross Margin 96.40
Profit Margin TOT -1.73
Income Statements
Revenue $235,224,000
Revenue Per Share $2.9175
Revenue 3 Years $-15.36
Revenue 5 Years $-1.36
Valuation Measures
PE Ratio -
Enterprise Value $533,298,009
Price To Sales 0.469586
Price To Free Cash 0.900000
PE High Last 5 Years -
Price To Book 0.6
Price To Cash Flow 0.7
PE Low Last 5 Years -
Price To Tangible Book -0.3
Financial Strength
Total Debt To Equity 2.5
Int Coverage 1.0
Current Ratio 0.8
Leverage Ratio 4.2
Quick Ratio 0.6
Long Term Debt To Capital 0.68
Assets
Receivables Turnover 4.5
Invoice Turnover 1.50
Assets Turnover 0.30
Management Effectiveness
Return Assets -0.44
Return On Equity -1.97
Return On Capital 5.99
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ASRT
Assertio T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.